dismiss

Need Spare Parts? Try the All-New Parts Hunter+EasyPay -- Learn more here

SEARCH
Current Location:
>
> This Story

(1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Dunlee to introduce new tube at RSNA Company confirms continued commitment to tube manufacturing

Radiotherapy steps outside of cancer treatment Shows promise for heart disease

Setting the Standard: XR-29 and the Importance of CT Dose Optimization Next step to reducing dose

Data collection system personalizes cancer treatment Predicts possible side effects

Hidden info in PET images aids cancer treatment Largest study of its kind

Survey shows U.S. hospital performance The health care system receives a mixed review

Standardizing breast density notification First bill that sets minimum federal standard

Medical technology benefits U.S. economy Study may settle the controversy

GE's Vizamyl shows promise in two studies Better predicts Alzheimer's disease

A step forward for proton therapy Smaller and less expensive systems

Bracco gets FDA nod to expand Multihance indications

by Brendon Nafziger , DOTmed News Associate Editor
Bracco Diagnostics Inc. said Friday it received Food and Drug Administration approval to expand the indications of an MRI imaging agent used to detect brain tumors to now cover certain types of arterial disease.

Bracco said the drug, Multihance (gadobenate dimeglumine), now has been expanded for use in magnetic resonance angiographies to help diagnose stenosis in the renal and aorto-ilio-femoral arteries. The gadolinium-based contrast agent was originally approved by the FDA in 2004 for MRI scans of the central nervous system in children and adults.

Story Continues Below Advertisement

Click here to Schedule a Demonstration With McKesson

McKesson Enterprise Medical Imaging Solutions Help Enhance Your Financial, Clinical & Operational Effectiveness. Learn more about McKesson solutions for radiology at McKesson.com/medicalimaging



The company said the approval came about after Bracco conducted two large, multi-center, prospective trials on the new indication.

As with other GBCAs, Multihance carries a black box warning label because of the risk of nephrogenic systemic fibrosis, believed to be an extremely rare side effect for patients with kidney problems who receive GBCA injections. However, in a statement, Dr. Alberto Spinazzi, senior vice president of regulatory affairs with Bracco, said Multihance carries a "strong record of safety" and has been administered more than 14 million times.

"Multihance has long been distinguished in the MRI of the CNS as a gadolinium-based contrast agent characterized by a strong increase in relaxivity in any medium containing serum proteins, contributing to increased contrast-to-noise ratio and lesion-to-brain ratio and improved visualization," he said.

Bracco Group is headquartered in Milan, Italy.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED